- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04641793
BoMI for Muscle Control
Body-Machine Interface for Recovering Muscle Control
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
When suffering from conditions affecting the central nervous system, such as spinal cord injury (SCI), stroke or neurodegenerative disorders, two pathways are available for regaining independence and quality of life. One way is through clinical interventions, including therapeutic exercises, often in combination with pharmacological agents. The other is provided by assistive technologies, such as wheelchairs or robotic systems. These two approaches have conflicting characteristics. While rehabilitation exercises challenge patients to use the most affected parts of their musculoskeletal apparatus, assistive technologies are typically designed to bypass the disability. This has led to divergent research domains. In both fields there are three major gaps that we plan to address in the investigator's research:
- High cost of technology and the limited amount of available hospital-based rehabilitation;
- Lack of adaptability of currently available assistive technologies, such as head switches and sip-and puff devices, that require users to overcome a hard learning barrier;
- Inadequate criteria for assessment of effectiveness of therapy, with common techniques still relying on subjective approaches that are inadequate considering the current state of biomedical science and technology.
We will address all of these issues by developing a new generation of body-machine interfaces (BoMI) supporting both assistive and rehabilitative goals. BMIs will translate movement signals and muscle activities of the user into control signals for assistive devices and computer systems. State-of-the-art systems for surface electromyography (EMG) and movement recording (IMU) will be integrated through machine learning techniques to facilitate sensorimotor learning while providing the means to promote or reduce the use of targeted muscles. New comprehensive assessment techniques will be developed by integrating standard measure of function - as the manual muscle test - with EMG analysis and non-invasive magnetic brain stimulation (TMS) (Magstim 200 Bistim, Whitland, UK). The development will be organized in three specific aims.
AIM 1: To develop a BMI integrating muscle activities and motion signals for operating external devices and performing rehabilitation exercises. EMG signals derived from multiple muscles in the upper body (e.g. deltoid, pectoralis, trapezius, triceps, etc.) will be integrated with motion signals to generate control signals for external devices (e.g. the coordinates of a cursor on a computer monitor or the speed and direction commands to a powered wheelchair). Both linear (PCA) and nonlinear maps (auto encoder networks) will be explored, although current preliminary evidence suggests that non-linear auto encoders (AE) are likely to better facilitate user learning1.
AIM 2: To enable targeting and modulating recruitment of specific muscles and muscle synergies during the practice of games and functional tasks. To enhance or reduce the role of a muscle or synergy, the output of the BoMI will be modulated in proportion to the deviation of the measured muscle activity from the desired level. The effectiveness of the approach will be tested at different times following training, both by tracking of motions and EMG activities during the performance of selected activities of daily living (ADL) and trough the assessment of muscle responses evoked by non-invasive brain stimulation.
AIM 3: To promote the adoption of the BoMI by facilitating access to its functions by patients and therapists and by performing an observational study on uptake in the DayRehabTM environment. The Shirley Ryan Ability Lab has established a unique environment in which spinal cord injured and stroke outpatients engage in daily rehabilitation exercises in close physical proximity with researchers. We will seize this opportunity to introduce the BoMI in the context of clinical therapy thus allowing a direct assessment of acceptance by therapists and clients.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ferdinando Mussa-Ivaldi, PhD
- Numéro de téléphone: 312 238 1230
- E-mail: sandro@northwestern.edu
Sauvegarde des contacts de l'étude
- Nom: Dalia De Santis, PhD
- Numéro de téléphone: 312 238 1650
- E-mail: ddesantis@sralab.org
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Shirley Ryan Ability Lab
-
Contact:
- Ferdinando Mussa-Ivaldi, PhD
- Numéro de téléphone: 312-238-1230
- E-mail: sandro@northwestern.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Uninjured individuals
Inclusion criteria:
- Ages 18 and up.
- Ability to follow simple commands, and to respond to questions.
Exclusion criteria for SCI participants:
• Does not meet the inclusion criteria.
Individuals with SCI
Inclusion criteria:
- Age 16-65
- Injuries at the C3-6 level, complete (ASIA A), or incomplete (ASIA B and C).
- Able to follow simple commands
- Able to speak or respond to questions
Exclusion criteria:
- Presence of tremors, spasm and other significant involuntary movements
- Cognitive impairment
- Deficit of visuo-spatial orientation
- Concurrent pressure sores or urinary tract infection
- Other uncontrolled infection, concurrent cardiovascular disease
- Sitting tolerance less than one hour
- Severe hearing or visual deficiency
- Miss more than six appointments without notification
- Unable to comply with any of the procedures in the protocol
- Unable to provide informed consent
- Stroke survivors:
Inclusion criteria:
- Recent stroke (Sub acute to early chronic, between 3 and 12 months from CVA)
- Age less than 75 (To avoid age-related confounds)
- Inability to operate a manual wheelchair
- Available medical records and radiographic information about lesion locations
- Significant level of hemiparesis (UE Fugl Meyer score between 10 and 30)
- Presence of pathological muscle synergies in the UE (flexor and/or extensor synergy)
Exclusion criteria:
- Aphasia, apraxia, cognitive impairment or affective dysfunction that would influence the ability to perform the experiment
- Inability to provide informed consent
- Severe spasticity, contracture, shoulder subluxation, or UE pain
- Severe current medical problems, including rheumatoid arthritis or other orthopaedic impairments restricting finger or wrist movement
Additional exclusion criteria for participants enrolled in TMS procedures
- Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere in the body. This applies to all metallic hardware such as cochlear implants, or an Internal Pulse Generator or medication pumps, implanted brain electrodes, and peacemaker.
- Personal history of epilepsy (untreated with one or a few past episodes), or treated patients
- Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
- Administration of drugs that potentially lower seizure threshold [REF], without concomitant administration of anticonvulsant drugs which potentially protect against seizures occurrence
- Change in dosage for neuro-active medications (Baclophen, Lyrica, Celebrex, Cymbalta, Gabapentin, Naprosyn, Diclofenac, Diazepam, Tramadol, etc) within 2 weeks of any study visit.
- Skull fractures, skull deficits or concussion within the last 6 months
- unexplained recurring headaches
- Sleep deprivation, alcoholism
- Claustrophobia precluding MRI
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SCI
|
We will consider two methods for integrating motions and EMG signals:
|
|
Expérimental: STROKE
|
We will consider two methods for integrating motions and EMG signals:
|
|
Expérimental: UNIMPAIRED
|
We will consider two methods for integrating motions and EMG signals:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time
Délai: during the intervention
|
Changing time to task completion
|
during the intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Muscle activity
Délai: baseline, during the procedure, at 1 week follow-up
|
EMG activity in targeted muscles
|
baseline, during the procedure, at 1 week follow-up
|
|
Cortico spinal connectivity
Délai: baseline, immediately after the intervention, at 1 week follow-up
|
Motor evoked potentials in selected muscles following TMS stimulation of M1
|
baseline, immediately after the intervention, at 1 week follow-up
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Ferdinando Mussa-Ivaldi, PhD, Northwestern University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU00210086
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .